Core Insights - HCW Biologics Inc. is participating in the 2025 GenScript Biotech Global Forum, focusing on challenges in cell and gene therapy (CGT) biomanufacturing and supply chain management [1][5] - Dr. Hing C. Wong, the Founder and CEO of HCW Biologics, will discuss how proprietary molecules developed by the company can reduce costs and enhance clinical efficacy in CGT [3][4] Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies aimed at extending healthspan by addressing chronic inflammation linked to various diseases [4] - The company has two drug discovery platforms, including the TOBI™ platform, which generates multi-functional fusion molecules with immunotherapeutic properties [4] Drug Development Focus - HCW Biologics categorizes its drug candidates into three classes: - Class I: Multi-Functional Immune Cell Stimulators - Class II: Second-Generation Immune Checkpoint Inhibitors and Multi-Specific Targeting Fusions - Class III: Enhanced Immune-Cell Engagers [2][4] - The company is targeting treatments for hematologic and solid tumors, virally infected cells, and age-related diseases [2][4] Industry Context - The GenScript Biotech Global Forum aims to address the rapid advancements and commercialization challenges in gene and cell therapy, highlighting the importance of collaboration among scientists, industry leaders, and regulatory bodies [5][6]
HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025